Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Vancomycin for Secondary Prophylaxis of CDI
NCT04000555Phase 4Terminated
- Sponsor
- University of South Florida
- Start
- Sep 2019
- Primary completion
- Jun 2022
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vancomycin in Clostridium difficile infection (CDI), sponsored by University of South Florida. Started Sep 2019; status: terminated.
02
Drugs
vancomycin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT04000555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000555.